Host genetic basis for hepatitis C virus clearance: A role for blood collection centers

Current Opinion in Hematology

Volumn 17, Issue 6, 2010, Pages 550-557

  Selvarajah, Suganya ^a   Tobler, Leslie H ^a   Simmons, Graham ^a   Busch, Michael P ^a  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

Author keywords

hepatitis C virus; hepatitis C virus clearance; hepatitis C virus host genetics; role for blood centers

Indexed keywords

INTERFERON LAMBDA 3; INTERLEUKIN 28; INTERLEUKIN 28B; INTERLEUKIN 29; UNCLASSIFIED DRUG;

BLOOD BANK; BLOOD DONOR; DISEASE COURSE; GENETIC ASSOCIATION; GENETIC LINKAGE; HEPATITIS C; HEPATITIS C VIRUS; HOST; HUMAN; IMMUNE RESPONSE GENE; IMMUNOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SCREENING; SINGLE NUCLEOTIDE POLYMORPHISM;

BLOOD BANKS; BLOOD SPECIMEN COLLECTION; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 78049265857     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833e7544     Document Type: Review

References (53)

1. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119: 1745-1754.
2. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008; 372: 321-332.
3. Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis 2008; 12:713-726; xi.
4. Sklan EH, Charuworn P, Pang PS, Glenn JS. Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol 2009; 6:217-227.
5. Post J, Ratnarajah S, Lloyd AR. Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009; 66:733-756.
6. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-714.
7. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl 1):74-81.
8. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562.
9. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13:2436-2441.
10. Centers for Disease Control. Surveillance of Acute Viral Hepatitis-US, 2007. MMWR 2009 50 (No. SS-3).
11. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol 2001; 8:200-206.
12. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31 (Suppl 1):9-16.
13. Alter HJ, Conry-Cantilena C, Melpolder J, et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26:29S-33S.
14. Mosley JW, Operskalski EA, Tobler LH, et al. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat 2008; 15:120-128.
15. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215-229.
16. Pereira AA, Jacobson IM. New and experimental therapies for HCV. Nat Rev Gastroenterol Hepatol 2009; 6:403-411.
17. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362:1292-1303.
18. FlisiakR, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent antihepatitisC effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008; 47:817-826.
19. Maheshwari A, Thuluvath PJ. Management of acute hepatitis C. Clin Liver Dis 2010; 14:169-176; x.
20. Farnik H, Mihm U, Zeuzem S. Optimal therapy in genotype 1 patients. Liver Int 2009; 29 (Suppl 1):23-30.
21. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450-456.
22. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39:1702-1708.
23. Hoofnagle JH, Wahed AS, Brown RS Jr, et al. Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J Infect Dis 2009; 199: 1112-1120.
24. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97:2709-2714.
25. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004; 5:237-245.
26. Thio CL, Thomas DL, Goedert JJ, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001; 184:16-21.
27. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305:872-874.
28. Lemon SM. Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 2010; 285:22741-22747.
29. Rauch A, Gaudieri S, Thio C, Bochud PY. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009; 10:1819-1837.
30. Thio CL, Goedert JJ, Mosbruger T, et al. An analysis of tumor necrosis factor alpha gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection. Genes Immun 2004; 5:294-300.
31. Kimura T, Saito T, Yoshimura M, et al. Association of transforming growth factor-beta 1 functional polymorphisms with natural clearance of hepatitis C virus. J Infect Dis 2006; 193:1371-1374.
32. Huang Y, Yang H, Borg BB, et al. Afunctional SNPof interferon-gammagene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA 2007; 104:985-990.
33. Mueller T, Mas-Marques A, Sarrazin C, et al. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. J Hepatol 2004; 41:652-658.
34. Lio D, Caruso C, Di Stefano R, et al. IL-10and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol 2003; 64:674-680.
35. OleksykTK, ThioCL, Truelove AL, et al. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 2005; 6:347-357.
36. Selzner N, McGilvray I. Can genetic variations predict HCV treatment outcomes? J Hepatol 2008; 49:494-497.
37. Shackel NA, McCaughan GW. Intrahepatic interferon-stimulated gene responses: can they predict treatment responses in chronic hepatitis C infection? Hepatology 2007; 46:1326-1328.
38. Mosbruger TL, Duggal P, Goedert JJ, et al. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 2010; 201:1371-1380.
39. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
40. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
41. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
42. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801. The investigators examined the association of IL-28B SNP rs12979860 with spontaneous HCV clearance using SNP analysis. The IL-28B SNP was found to be the strongest predictor of spontaneous HCV clearance reported to date.
43. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL-28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-1345; 1345 e1-7. The authors performed GWAS for individuals with different HCV disease outcomes that included those who spontaneously cleared the virus, responded to treatment or were chronically infected. They used a cohort of Swiss whites for their analysis.
44. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4:63-68.
45. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69-77.
46. Van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006; 25:361-372.
47. Pagliaccetti NE, Eduardo R, Kleinstein SH, et al. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 2008; 283:30079-30089.
48. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131:1887-1898.
49. Stramer SL. Nucleic acid testing for transfusion-transmissible agents. Curr Opin Hematol 2000; 7:387-391.
50. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50:1495-1504.
51. Murphy E, Fang J, Tu Y, Cable R. Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies and body mass index. J Infect Dis 2010; Jul 9 [Epub ahead of print].
52. Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351:760-768.
53. Bernardin F, Tobler L, Walsh I, et al. Clearance of hepatitis Cvirus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 2008; 47:1446-1452.